Chest:重症监护室脓毒症1和脓毒症3的临床评估

2017-07-14 xiangting MedSci原创

脓毒症3诊断标准以敏感性为代价缩小了脓毒症人群,造成的假阴性可能会延迟疾病诊断。

目前脓毒症1与脓毒症3的标准之间存在相当大的争议。研究人员从MIMIC-III数据库中选择ICU入院第一天符合SIRS≥2标准(脓毒症1)或SOFA评分≥2(脓毒症3)的感染患者,并使用全因死亡率作为终点比较其结局。还根据此前慢性器官功能障碍进行亚组分析。

共纳入21,491例感染患者。在符合脓毒症1诊断标准的患者中,13.42%没有满足脓毒症3标准,这个人群的21天死亡率为6.96%。相比之下,满足脓毒症3标准的患者中,7.00%没有达到脓毒症1标准,其21天死亡率为10.76%。当排除先前存在的器官疾病时,18.41%的脓毒症1患者不符合脓毒症3标准,21天死亡率为6.39%,6.00%脓毒症3患者不符合脓毒症1标准,21天死亡率为9.11%。当应用SIRS≥2或SOFA≥2标准预测未发生慢性器官功能障碍的感染患者的21天全因死亡率时,灵敏度分别为96.0%或91.0%。虽然SOFA和SIRS标准的AUCs可用于预测死亡率,SOFA评分代表病情的严重程度,而SIRS评分代表了临床上宿主对感染的反应。

脓毒症3诊断标准以敏感性为代价缩小了脓毒症人群,造成的假阴性可能会延迟疾病诊断。在定义脓毒症3时,比较SIRS和SOFA标准的预测性能可能是不合适的。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1929377, encodeId=132619293e779, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Oct 27 22:44:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1740894, encodeId=db321e40894ee, content=<a href='/topic/show?id=9c76230166d' target=_blank style='color:#2F92EE;'>#临床评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23016, encryptionId=9c76230166d, topicName=临床评估)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e55d34837992, createdName=12498dabm88暂无昵称, createdTime=Mon Sep 25 07:44:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050773, encodeId=d9ea2050e7351, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Mar 04 00:44:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551114, encodeId=9a74155111401, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Sun Jul 16 01:44:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222207, encodeId=96b022220e66, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jul 14 11:27:37 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2017-10-27 Smile2680
  2. [GetPortalCommentsPageByObjectIdResponse(id=1929377, encodeId=132619293e779, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Oct 27 22:44:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1740894, encodeId=db321e40894ee, content=<a href='/topic/show?id=9c76230166d' target=_blank style='color:#2F92EE;'>#临床评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23016, encryptionId=9c76230166d, topicName=临床评估)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e55d34837992, createdName=12498dabm88暂无昵称, createdTime=Mon Sep 25 07:44:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050773, encodeId=d9ea2050e7351, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Mar 04 00:44:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551114, encodeId=9a74155111401, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Sun Jul 16 01:44:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222207, encodeId=96b022220e66, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jul 14 11:27:37 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1929377, encodeId=132619293e779, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Oct 27 22:44:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1740894, encodeId=db321e40894ee, content=<a href='/topic/show?id=9c76230166d' target=_blank style='color:#2F92EE;'>#临床评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23016, encryptionId=9c76230166d, topicName=临床评估)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e55d34837992, createdName=12498dabm88暂无昵称, createdTime=Mon Sep 25 07:44:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050773, encodeId=d9ea2050e7351, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Mar 04 00:44:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551114, encodeId=9a74155111401, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Sun Jul 16 01:44:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222207, encodeId=96b022220e66, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jul 14 11:27:37 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1929377, encodeId=132619293e779, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Oct 27 22:44:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1740894, encodeId=db321e40894ee, content=<a href='/topic/show?id=9c76230166d' target=_blank style='color:#2F92EE;'>#临床评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23016, encryptionId=9c76230166d, topicName=临床评估)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e55d34837992, createdName=12498dabm88暂无昵称, createdTime=Mon Sep 25 07:44:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050773, encodeId=d9ea2050e7351, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Mar 04 00:44:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551114, encodeId=9a74155111401, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Sun Jul 16 01:44:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222207, encodeId=96b022220e66, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jul 14 11:27:37 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2017-07-16 bioon6
  5. [GetPortalCommentsPageByObjectIdResponse(id=1929377, encodeId=132619293e779, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Oct 27 22:44:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1740894, encodeId=db321e40894ee, content=<a href='/topic/show?id=9c76230166d' target=_blank style='color:#2F92EE;'>#临床评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23016, encryptionId=9c76230166d, topicName=临床评估)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e55d34837992, createdName=12498dabm88暂无昵称, createdTime=Mon Sep 25 07:44:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050773, encodeId=d9ea2050e7351, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Mar 04 00:44:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551114, encodeId=9a74155111401, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Sun Jul 16 01:44:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222207, encodeId=96b022220e66, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jul 14 11:27:37 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2017-07-14 1e0f8808m18(暂无匿称)

    学习了,谢谢分享。

    0

相关资讯

J Crit Care:脓毒症急性肾损伤不良预后的临床因素及肾替代治疗时机

脓毒症导致的急性肾损伤(SA-AKI)患者死亡率的受一些临床因素的影响,以这些因素变化决定接受连续性肾脏替代治疗(CRRT)实施时机。

Minerva Anestesiol:从分子层面探讨脓毒症引起的急性肾损伤

在重症病房里,40%-50%的脓毒症患者都会发生急性肾脏损伤,但脓毒症患者与急性肾损伤(AKI)之间的分子差异仍知之甚少。在这里,我们研究了脓毒症患者基因表达的变化,结合传统的肾脏生理参数,找出不同基因对AKI发生的影响。

Environ Pollut:对疑似脓毒症的急诊患者:微生物学结果和抗生素过度使用

本研究旨在于研究急诊科(ED)住院病人中脓毒症患者的细菌感染和抗生素使用情况。

Minerva Anestesiol:持续血液净化治疗对治疗脓毒症和ARDS究竟有效吗—一项系统评价和meta分析

在重症病房里,严重脓毒症/脓毒症休克和急性呼吸窘迫综合征(ARDS)等严重感染类疾病发病率居高不下,此类疾病也成为导致ICU患者死亡的头号杀手。此次,我们对数十项随机试验进行meta分析,用以评估连续静脉静脉血液滤过(CVVH)是否可以降低此类疾病的死亡率。

Crit Care Med:严重脓毒症或脓毒性休克:抗菌药物用晚了有多悲剧?

2017年6月,发表在《Crit Care Med》的一项由美国科学家进行的研究,考察了急诊科医生对脓毒症患者开始抗菌药物治疗的时间差异。

Crit Care Med:脓毒症患者第二剂抗菌药物延迟 后果很严重

2017年6月,发表在《Crit Care Med》的一项由美国科学家进行的研究从急诊入院的脓毒症患者第二剂抗菌药物延迟:发生率、危险因素及结局